; Benjamin Tang, MD [9] [10] [11] [12] ; Marshall Nichols, MS 4 ; Christopher W. Woods, MD 4, 13, 14 S epsis is defined as life-threatening organ dysfunction resulting from a dysregulated immune response to infection (1) . Despite its association with nearly half of all in-hospital deaths, there are still no approved therapies specific for sepsis (2, 3) . In part, this is because the clinical syndrome of sepsis includes substantial heterogeneity and may in fact encompass many different subtypes, analogous to what is well established among patients with cancer (4, 5) . Current sepsis groupings are based on clinical criteria such as the presence of shock, infection source, or organ failure, but such groupings may not represent the driving biology of the host response. They have also failed to adequately match patients for novel interventions. If the heterogeneity of sepsis truly reflects heterogeneity in the host response, characterization of these underlying host response types will be fundamental to enabling precision sepsis therapeutics (6) .
In unsupervised analysis, data are sorted into subgroups ("clusters") that are defined only internally and without reference to external "supervisory" outcomes, such as mortality or severity. Instead, the structure inherent within the data is used to define the subgroups. Such data-driven analyses have been successful in defining validated, clinically relevant disease subtypes in multiple diseases (4, 5, 7, 8) . Since whole blood gene expression reflects the temporal state of the circulating leukocytes, at least two academic groups have applied unsupervised clustering to whole blood transcriptomic profiles in patients with sepsis to study the "host response" in a data-driven framework (9) (10) (11) (12) (13) . Their results have identified higher mortality subtypes with evidence of immune exhaustion and diminished glucocorticoid receptor signaling, as well as lower mortality subtypes with conventional proinflammatory signaling (9) (10) (11) (12) (13) .
Clustering analyses often yield nonreproducible results for one of two reasons: either multiple arbitrary choices in methodology are used such that minor changes in analysis yield new results or the clustered dataset is too small and not representative of the broad heterogeneity of a disease. However, recent advances in meta-clustering and data pooling can help solve both problems (14) (15) (16) . Coupled with an unprecedented amount of publicly available transcriptomic data in sepsis (17, 18) , here we tested the hypothesis that there exist robust, reproducible sepsis host response subtypes (clusters) across the broad, heterogeneous spectrum of clinical sepsis.
METHODS

Systematic Search and Dataset Criteria
We performed a systematic search of Gene Expression Omnibus and ArrayExpress for gene expression studies of clinical studies in sepsis, as previously described (16) . Individual datasets were renormalized as previously described (18) . Datasets were only included if they studied whole blood gene expression at hospital or ICU admission (i.e., primary admission for sepsis). Since the host response differs substantially between bacterial and viral infections (15, 19) , an unsupervised analysis would likely lead to groupings primarily based on infection type. We thus removed all samples with microbiologically confirmed viral infection unless a microbiologically confirmed bacterial infection was also present (only three confirmed coinfections were included). Studies that did not supply sample-level microbiological data but were identified in their article as being drawn from patients with primarily bacterial sepsis were treated as all bacterial. We further removed patients who were sampled more than 48 hours after sepsis diagnosis given the potential impact of treatment on the host response (20, 21) . All data used herein were deidentified and publicly available and so exempt from Institutional Review Board review.
Pooling Data With COmbat CO-Normalization Using conTrols to Enable Clustering
The recent development of the COmbat CO-Normalization Using conTrols (COCONUT) method (15) allows for bias-free For information regarding this article, E-mail: tes17@alumni.stanford.edu; pkhatri@stanford.edu correction of batch effects between multiple microarray datasets, enabling pooled analysis, provided that healthy controls are present. The core assumption is that healthy controls across datasets come from the same statistical distribution. This assumption allows for the calculation of correction factors that remove technical differences across pooled datasets without bias to the number or type of diseased samples present.
We split the datasets into "discovery" and "validation" groups based on whether healthy controls were present in the dataset, specifically, so that we could use the COCONUT method. Since the inclusion of healthy controls in any given dataset is essentially random, the discovery/validation split was not expected to introduce bias. We used the COCONUT method to conormalize the discovery datasets into a single pool and then removed all healthy controls from further analysis.
Clustering the Discovery Data Using COmbined Mapping of Multiple clUsteriNg ALgorithms
In order to determine how many clusters were present in the COCONUT conormalized discovery data, we used the COmbined Mapping of Multiple clUsteriNg ALgorithms (COMMU-NAL) method, which integrates data from multiple clustering algorithms and validity metrics across a range of included variables to identify the most robust number of clusters present in the supplemental data (Supplemental Digital Content 1, http:// links.lww.com/CCM/D419) (14) . We ranked the top 5,000 genes across the discovery datasets using an algorithm that accounts for both within-dataset variance and between-dataset variance (16) . We ran COMMUNAL using consensus clustering versions of two algorithms, K-means clustering and Partitioning Around Medioids (PAM), due to their robustness in large, noisy datasets. Both methods were run across a range of variables from 100 genes up to 5,000 genes (in ranked order). COMMUNAL then integrated these data (at its default variables) to produce an optimality map of clustering. In the resulting map, the most stable optima were taken as indicating the most robust clustering.
Having chosen an optimal clustering using COMMUNAL, we integrated the sample assignments between clustering algorithms (i.e., the clusters into which the PAM and K-means algorithms assigned samples). The COMMUNAL method assigned all samples for which the clustering algorithms agreed to discovery clusters and removed all samples for which there was disagreement between the PAM and K-means methods as "unclustered." The hypothesis is that not every sample may be perfectly assigned to a given cluster (e.g., some samples may exhibit biology suggestive of two clusters). Since classifiers trained on data with fewer errors are more robust, removing these uncertain samples improves the classifier accuracy. Note that the classifier built for validation does not produce "unclustered" assignments (supplemental data, Supplemental Digital Content 1, http://links.lww.com/CCM/D419).
To check whether the discovery clusters appeared to be separated in gene expression space, we visualized them using both heat maps and principal component analyses. We further used pooled sample-level demographic and phenotypic data to investigate clinical differences between discovery clusters.
Biological and Clinical Investigations
The details of our treatment of complex clinical variables including illness severity, immunosuppression, and coagulopathy are explained in the supplemental data (Supplemental Digital Content 1, http://links.lww.com/CCM/D419). Gene Ontology (GO) analysis (22) , the construction of a cluster classifier (23) , and testing of the validation datasets are described in the supplemental data (Supplemental Digital Content 1, http://links.lww.com/CCM/D419).
Jargon-Free Summary
In recognition of the highly technical nature of the article, we have prepared a "jargon-free summary" of the methods and results. This is available in the supplemental data (Supplemental Digital Content 1, http://links.lww.com/CCM/D419).
RESULTS
An explanatory infographic, along with online interactive visualizations of the COMMUNAL clustering output and PCA analysis, can be viewed at http://shiny.cac.queensu.ca/CritCareMed/ transcriptomic_clusters/.
Included Studies, COCONUT Conormalization, and COMMUNAL Cluster Selection
We first hypothesized that robust molecular subgroups exist in patients with bacterial sepsis. We thus performed a unified clustering across 14 bacterial sepsis discovery datasets from eight different countries (n = 700) ( Table 1) using COCONUT conormalization (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) . We identified nine validation datasets from five different countries that matched inclusion criteria but did not include healthy controls (n = 600) ( Table 2 and Fig. 1 ) (12, (38) (39) (40) (41) (42) (43) . We first conormalized the 14 discovery datasets into a single pooled cohort using the COCO-NUT method (15) , providing batch-corrected, pooled sepsis data across a wide variety of clinical conditions ( Supplemental Fig.  1 , Supplemental Digital Content 1, http://links.lww.com/CCM/ D419). There were 8,946 genes that were measured in all 14 pooled discovery datasets. The pooled data were then clustered using the COMMUNAL algorithm across 11 test points ranging from the top 100 to 5,000 genes using consensus K-means and consensus PAM clustering (individual clustering algorithm results shown in Supplemental Fig. 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/D419) (14) . Visual inspection of the COMMUNAL optimality map showed clear, stable optima at K = 3 clusters from 500 genes to 5,000 genes (Supplemental Fig. 3 , Supplemental Digital Content 1, http://links.lww.com/ CCM/D419). Further, we chose the clustering at 500 genes as the optimal clustering assignment under the assumption that using the fewest number of genes had the least amount of noise or redundant signal. Based on GO analysis described below, and to facilitate their easier understanding, we have named the three clusters "Inflammopathic," "Adaptive," and "Coagulopathic."
To visualize their general separability, we performed principal components analysis on the discovery clusters using all genes both with and without the "unclustered" samples ( Fig. 2) . Details on the assignment of clusters in the 
GO Across the Different Clusters
To better understand the biology represented by the clusters, we used GO overrepresentation analysis. We assigned each of the 500 genes to one of the three discovery clusters based on absolute effect size (i.e., each gene was assigned to the cluster in which it was most different from the remaining two clusters). We then tested each of the resulting three gene lists for significance in GO terms (Supplemental Table 3 , Supplemental Digital Content 3, http://links.lww.com/CCM/D421). The Inflammopathic cluster was significant for canonical proinflammatory signaling pathways such as interleukin (IL)-1 receptor, pattern recognition receptor activity, and complement activation. The Adaptive cluster was significant for several pathways related to adaptive immunity and interferon signaling. The third cluster was named Coagulopathic as it was significant for terms related to clotting and coagulation, such as platelet degranulation, glycosaminoglycan binding, and coagulation cascade.
Clinical Findings Across the Different Clusters
We investigated the differences between the discovery clusters in the demographic and clinical variables for which we had subject-level data ( Table 3) . We found significant differences in age (both the overall distribution and the percent of patients > 70 yr old), severity (as measured by percent of patients with clinical severity scores above the dataset mean and/or in septic shock), and 30-day mortality. We also found that the Inflammopathic cohort had greater bandemia and a lower lymphocyte percentage on WBC differential; however, differential was only available in a single cohort. This suggests that the Adaptive cluster is comprised of less sick patients with fewer elderly patients, whereas the Inflammopathic and Coagulopathic clusters separate the sicker patients into a younger and an older group. Addition of the "unclustered" patients showed that they have a balanced phenotype with respect to age and shock; their addition did not substantially change the demographic or clinical findings (Supplemental Table 4 , Supplemental Digital Content 1, http://links.lww.com/CCM/D419). Since the unsupervised clustering did not take into account any clinical data whatsoever, finding a significant difference in mortality suggests that the clusters may represent distinct pathophysiologic states of clinical relevance.
We ran regression models on cluster membership (in a "1-vs-all" format) to assess the joint ability of age, shock, severity, and their interaction to predict cluster membership. In each case, the percent of variance explained by age, shock, and severity was 9.7%, 6.4%, and 0.7% for the Inflammopathic, Adaptive, and Coagulopathic groups, respectively, in discovery (total n = 251) (Supplemental Table 5 , Supplemental Digital Content 1, http://links.lww. com/CCM/D419). A sensitivity analysis showed that these results could only be explained away by an unmeasured confounding variable with a substantially greater effect size than the included variables (Supplemental Table 5 , Supplemental Digital Content 1, http://links.lww.com/CCM/ D419). Thus, while age, shock, and severity are significantly different across the groups, cluster assignment is much more complex than these three factors alone.
Validation of Cluster Classifier in Independent Datasets
Having characterized the sepsis clusters in the discovery datasets, we next hypothesized that these same clusters could be recovered in independent validation datasets using a discrete classifier. We next built a gene expression-based classifier for cluster assignment, so that the cluster hypothesis could be tested and applied in external validation datasets. Briefly, the classifier assigns each sample three scores (one for each cluster type) and then applies multiclass regression to output a final cluster assignment (Supplemental Table  6 , A and B, Supplemental Digital Content 1, http://links.lww.com/ CCM/D419). The classifier used a total of 33 genes and yielded an overall 83% accuracy in leaveone-out reassignment of the samples on which it was trained (Supplemental Table 6C , Supplemental Digital Content 1, http:// links.lww.com/CCM/D419). The greatest classifier inaccuracy is in distinguishing Inflammopathic patients from Coagulopathic patients (Supplemental Fig. 6 , Supplemental Digital Content 1, http://links.lww.com/CCM/ D419). We applied the classifier to the nine bacterial sepsis validation datasets (Supplemental Table 7 , Supplemental Digital Content 1, http://links.lww.com/CCM/D419) (12, (38) (39) (40) (41) (42) (43) (44) and judged the classifier's accuracy by its ability to recover clusters with similar molecular and clinical phenotypes to the discovery clusters. Since the nine validation datasets are independent from one another, we examined the same demographic and clinical variables as in the discovery clusters in both a pooled fashion ( Table 4 ) and treating each dataset independently (Supplemental Table 8 , Supplemental Digital Content 1, http://links.lww.com/CCM/D419).
As the individual datasets may be underpowered to detect differences, we ran statistical tests in the pooled data; compared with the discovery clusters, we observed the same patterns of significance. The Coagulopathic cluster had significantly more patients older than 70 years (p < 0.05), whereas the Adaptive cluster had fewer patients with shock (p < 0.01), fewer patients with high clinical severity (p < 0.05) and a lower mortality (p = 0.01). The Coagulopathic cluster also was associated with clinical coagulopathy, including disseminated intravascular coagulation (p < 0.05) (Supplemental Tables 9 
Molecular Similarity Between Clusters Identified in Discovery and Validation
Since the validation clusters were assigned with information from only 33 genes, we investigated whether similar biology was present in the full gene expression profiles across discovery and validation clusters. First, we calculated the mean gene expression profiles for all 500 clustering genes and tested for correlation between the clusters. Significant correlation would indicate that the classifier was capturing most of the information from the original clustering; the 33 genes used in the classifier were thus excluded from this analysis to avoid bias. Pearson correlations in mean gene expression profiles within the assigned clusters were high (Inflammopathic cluster, 0.59 ± 0.18; Adaptive cluster, 0.67 ± 0.19; Coagulopathic cluster, 0.20 ± 0.21) (Fig.  3A) . These correlations were significant (p < 0.01) between the discovery and validation clusters for all datasets for Inflammopathic, all datasets for Adaptive, and five of nine datasets for Coagulopathic. As a comparison, 1,000 random samples of 500 genes yielded mean correlations of 0.01-0.02.
We next tested whether the same GO codes were overrepresented between validation clusters, as compared to the discovery clusters (Fig. 3B) . On average, 68%, 87%, and 61% of the codes found significant at p value of less than 0.01 in the discovery clusters (Inflammopathic, Adaptive, and Coagulopathic, respectively) were identified as significant at p less than 0.05 in the same clusters in validation. In addition, a block structure is seen within clusters of the same type, indicating generally shared pathway enrichment within cluster types.
Comparison to Previously Established Sepsis Endotypes
Two groups have previously performed clustering using sepsis transcriptomic profiles: Wong et al (9-11) and Davenport et al (12, 13) . We compared our cluster assignments with the previously published assignments and showed significant overlaps with the Inflammopathic and Adaptive clusters (Supplemental 
DISCUSSION
We here performed an unsupervised clustering analysis on pooled transcriptomic profiles (n = 700) from 14 datasets from a broad range of subjects with bacterial sepsis, demonstrating that there are three robust sepsis clusters (or "endotypes"). We have named these clusters Inflammopathic (higher mortality, innate immune activation), Adaptive (lower mortality, adaptive immune activation), and Coagulopathic (higher mortality, older, and with clinical and molecular evidence of coagulopathy), based on their molecular and clinical profiles. Next, we showed that a 33-gene classifier that assigns subjects to these three clusters is able to recover the clinical and molecular phenotypes in nine independent validation datasets (n = 600). Finally, we showed that these clusters can significantly explain the clusters derived by independent groups using different methods (9, 12) . Taken together, these results demonstrate that the host response in the sepsis syndrome can be broadly defined by these three robust clusters.
Notably, each of the validation datasets had separate inclusion/exclusion criteria, providing a sort of sensitivity analysis that the identified clusters appear in both pooled settings (as in discovery) but also in more uniform, carefully phenotyped cohorts. For instance, we pooled samples from pediatric and adult datasets in discovery, but our methods did not simply cluster patients by age; then in validation, two datasets were pediatric and seven were adult, but all datasets contained a mix of all three sepsis clusters. The fact that we redemonstrate the same broad phenotypic and molecular differences in these independent applications of the cluster classifier is strong evidence that cluster membership is present across populations.
Despite the outcome differences across our three clusters, their clinical utility is not merely the ability to risk stratify in terms of mortality. Mortality prediction is better achieved through purpose-built classifiers, which have been demonstrated with these same data (18) . Instead, the hypothesis that underlies the search for sepsis clusters is that "sepsis" represents multiple different disease states and manifests in many different ways (3, 6, 45) . The aim of our study was thus to uncover these subclinical clusters using a very large pool of sepsis patients across a wide range of clinical conditions. Uncovering and defining this heterogeneity may allow for greater success in the discovery and validation of therapies that are beneficial only to one sepsis cluster, but may be neutral or even harmful to other clusters (11) . For instance, both the molecular and clinical data suggest that the Coagulopathic cluster may be associated with functional coagulopathy. Given the association of sepsis with clinical coagulopathies, and despite (or perhaps because of) the failure of most therapeutic interventions for coagulopathy in sepsis (3, 46, 47) , further study of the Coagulopathic cluster is warranted. Similarly, drugs being tested in sepsis that are known to modulate the innate or adapative immune systems (such as anti-IL-1 or anti-Programmed Death-Ligand 1 treatments [48, 49] ) may potentially find efficacy in the Inflammopathic or Adaptive clusters, respectively.
We inferred pathobiology for the clusters by assigning each gene to the cluster in which it showed the greatest differential change from the other clusters. For instance, the association of innate immune pathways in the Inflammopathic cluster is indicative not of "normal" innate immune activation but rather of overactivation of the innate immune system or of a relative lack of activation of adaptive immune genes, in Inflammopathic patients compared with other septic patients. Similarly, the relatively higher adaptive immune gene activation in the Adaptive cluster may be linked to its lower mortality. Seen through this lens, the three sepsis clusters show biological insights that, to some degree, reflect clinical intuitions. The early overactivation of the innate immune system or coagulation cascade in sepsis is linked to higher mortality, while the relative lack of these changes and the expansion of the adaptive immune response may be linked to better outcome (50) . Furthermore, since genes were selected based on absolute effect size, similarity in GO pathway analysis between Inflammopathic and Adaptive clusters could be reflective of opposite modulation of similar pathways; this is further suggested by the strong inverse correlation between the Inflammopathic and Adaptive clusters in Figure 2 . As above, these biological insights might allow for hypotheses about guided treatments for different subtypes. Still, we only included subjects at admission for sepsis; whether and how these profiles might change depending on time since initial infection onset, longitudinally during treatment, or whether patients might move between subtypes over time, is unknown.
Two independent research groups have identified sepsis subgroups similar to those described here: one focused on pediatric sepsis in a U.S.-based cohort (9, 10) and the other focused on adult sepsis in U.K.-based cohorts (12, 13) . Notably, the two subgroupings do not broadly overlap. Comparison of our three clusters with the prior clusterings yielded several interesting findings. First, using subject-level comparisons, patients assigned to the Inflammopathic cluster were mostly assigned to Endotype B (11) or Sepsis Response Signature (SRS) 1 (12) . However, Endotype B conferred a lower mortality in children compared with Endotype A, whereas SRS 1 conferred a higher mortality in adults compared with SRS2. Still, we are reassured that these independent studies identified the same grouping of patients using completely separate techniques. Similarly, patients assigned to the Adaptive cluster were primarily assigned to SRS 2; both studies identified this as a low mortality group associated with interferon signaling. We also identified a third (Coagulopathic) cluster. It is possible that the substantially larger sample size and greater heterogeneity of our discovery cohorts compared with prior work allowed us to detect this third Coagulopathic cluster.
Our study has some limitations. First, we provided validation only in historic independent datasets, not in a prospectively collected cohort. This limited us to only nontargeted gene expression profiling (microarrays and RNA sequencing). Second, we examined only datasets of patients with bacterial sepsis at admission because the clustering algorithms may otherwise have been overwhelmed by the differing host responses to different types of infections (15, 19) . The coming availability of rapid host response diagnostics to distinguish between bacterial and viral infections (15, 40, 51) suggests that the cluster classifier could be applied to patients after diagnosis with bacterial infections. However, it is unknown whether these subtypes exist in patients with viral or fungal sepsis or in noninfected critically ill patients. Third, one of the validation datasets (GSE74224) reused 21 samples (20% of its total) from one of the discovery datasets (GSE28750), although they were reprofiled using a different technology (29, 42) . Exactly which samples are duplicates are unknown, so they could not be removed; however, this makes up less than 4% of the total validation samples, suggesting that results are unlikely to be affected. Finally, we have presented analyses for all clinical variables that were available in more than one study at the sample level. This led to the inclusion of some analyses that were individually underpowered. In addition, variables may not be missing at random; it is thus possible that missingness biases the outcome (for instance, by not reporting mortality in less severe cohorts). The various weaknesses make clear that a prospective clinical study of the clusters will be necessary to confirm and extend our results.
Overall, we used state-of-the-art methods in bioinformatics and data analysis to create the largest known unbiased pool of sepsis transcriptomic profiles and to then show that three robust, distinguishable clusters exist across the sepsis spectrum. These sepsis clusters could feature prominently in the clinical trials domain, where they may serve as an enrichment tool or a companion diagnostic. The confirmation that multiple subtypes exist within the host response will hopefully enable more research into a precision medicine approach for sepsis.
